Table 5.

Studies of antiresorptive drugs for the prevention of skeletal-related events in castration-resistant prostate cancer

	Drugs studied	Study duration (months)	Patients with skeletal- related events	Median time to first skeletal-related event (months)	Time to first and subsequent skeletal-related events
Saad et al (2004)⁵	Zoledronic acid (n=214) vs placebo (n=208)	24^*	81 (38%) vs 101 (49%); p=0·028	16·0 vs 10·5; p=0·009	HR 0·64 (95% CI 0·485–0·845); p=0·002
Small et al (2003)¹⁹	Pamidronic acid (n=169) vs placebo (n=181)	6·8^†	42 (25%) vs 46 (25%); p value not reported	Not tested	Not tested
Fizazi et al (2011)	Denosumab (n=950) vs zoledronic acid (n=951)	41^‡	341 (36%) vs 386 (41%)	20·7 (95% CI 18·8–24·9) vs 17·1 (15·0–19·4); p=0·0002 (non-inferiority), p=0·008 (superiority)^§	RR 0·82 (95% CI 0·71–0·94); p=0·008^§

n=number of patients. HR=hazard ratio. RR=rate ratio.

Fixed interval study with maximum of 24 months’ treatment duration.

^†

Fixed interval study with maximum of 27 weeks’ treatment duration.

^‡

Event-driven study with maximum of 41 months’ treatment duration.

^§

All randomised patients; p values were adjusted for multiplicity.